Ensuring Access and Approval for Innovative Therapies in Scleroderma

Clinical research and development programs for innovative therapies in scleroderma must accommodate the diverse data needs of multiple stakeholders. This white paper explores the requirements to create an integrated program capable of demonstrating the “value” of a new product, as well as clinical utility and therapeutic novelty.

Questions about an upcoming Clinical Trial?